Insider Selling: Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells 213 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 213 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $48.53, for a total value of $10,336.89. Following the completion of the transaction, the chief executive officer now directly owns 40,916 shares of the company’s stock, valued at $1,985,653.48. This represents a 0.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $45.63, for a total value of $136,890.00.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The stock was sold at an average price of $60.08, for a total transaction of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total transaction of $126,020.00.

Kewaunee Scientific Trading Down 1.5 %

Shares of NASDAQ KEQU opened at $40.00 on Thursday. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average price is $56.58 and its two-hundred day moving average price is $47.50. Kewaunee Scientific Co. has a 52-week low of $30.82 and a 52-week high of $71.33. The stock has a market capitalization of $114.20 million, a P/E ratio of 6.34 and a beta of 0.71.

Kewaunee Scientific (NASDAQ:KEQU) last posted its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. The business had revenue of $67.17 million for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research note on Friday, March 14th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in shares of Kewaunee Scientific by 2,605.9% during the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock valued at $28,000 after buying an additional 443 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of Kewaunee Scientific during the 4th quarter worth approximately $36,000. JPMorgan Chase & Co. raised its position in shares of Kewaunee Scientific by 18,000.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock worth $30,000 after purchasing an additional 900 shares during the period. Morgan Dempsey Capital Management LLC acquired a new position in Kewaunee Scientific during the 4th quarter valued at approximately $106,000. Finally, Barclays PLC acquired a new position in Kewaunee Scientific during the 3rd quarter valued at approximately $121,000. 32.69% of the stock is currently owned by institutional investors.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.